EBD Group Adds Updates to BIO-Europe Day 1 Program

ZURICH & MUNICH--(BUSINESS WIRE)-- In only four weeks, life science industry leaders will descend upon Munich, Germany as BIO-Europe 2010 assembles for the 16th consecutive year. The three-day event will welcome more than 2,700 attendees representing about 1,500 companies and will feature panels and workshops on effective partnering and development strategies.

The updated day 1 program features a full plate of insightful sessions and presentations. For an in-depth review of the program, please visit http://www.ebdgroup.com/bioeurope/program/index.php

Is Corporate Venture Replacing Traditional Venture Capital?
This panel will explore how corporate venture funds are positioned and structured in order to manage their dual role as investors and consortial partners with VC firms, as well as dealmakers to capture innovative developments and strategic assets for their parent companies. In addition, activities of corporate venture funds are also viewed from the perspective of a funded company. Moderator Siegfried Bialojan, Ernst & Young will be joined by panelists Markus Goebel, Novartis Venture Funds; Christoph Huels, Merck Serono; Sven Rohmann MD, PhD, Burrill & Company; and Christian Zahnd, Molecular Partners.

The Pendulum Swings: A Look Back at 2010 and Prospects for the Year Ahead
Ben Bonifant of Campbell Alliance will lead an interactive discussion with Frank Borriello, Millennium: The Takeda Oncology Company; Susanne Kreutz, Bayer Schering Pharma AG; Sunil Patel, OncoMed Pharmaceuticals; and Shanon Thomas, Seattle Genetics on licensing trends thus far in 2010. The panel will examine two deals that are indicative of this year’s deal landscape, and discuss prospects for 2011.

The $100 Million Deal
In an effort to align risk with reward, pharma has been pushing for smaller upfront payments and a series of milestones if performance targets are met. Stuart Collinson, Forward Ventures, will lead a panel of different stakeholders, including venture, pharma and biotech in a discussion of what back loaded deal structures mean for them. They will consider what factors influence deal structures (such as the absence of an IPO alternative, regional deals and competitive processes), and how biotech companies should be built if structured transactions continue to be prevalent in the future.

Business Models that Work
Karen Bernstein of BioCentury will be joined by Tim Edwards, Cellzome; Simon Moroney, MorphoSys AG; Edwin Moses, Ablynx NV; Francesco De Rubertis, Index Ventures / Index Seed; and Onno van de Stolpe, Galapagos NV in a look at new strategies for drug development from precompetitive work and translational science, to incubator-like spaces being set up by big pharma and different collaboration models among industry players, all the way up to changing models on the marketing end.

Biotech Innovation and Access to Capital in an Era of Reform
Alan Eisenberg of BIO will lead a panel that features Gary L. Geipel, Lilly Deutschland; Paul Hastings, OncoMed Pharmaceuticals; and Vaughn Kailian, MPM Capital in a discussion of how recently enacted and pending policies are viewed by the biotech and life science investor community and their likely short term, long term and cumulative impact on the industry.

The Diabetes Dealmaking Dilemma
Led by Lionel Carnot of Bay City Capital, an expert panel will explore the reasons for a decreasing level of innovation in the diabetes space, and the partnering potential for existing treatment candidates. They will also discuss possible new sources of innovation for diabetes treatment as well as if and how existing hurdles to partnering success can be overcome.

The Future of Diagnostics' Partnering Strategy
Much has been said regarding the evolving role biomarkers and companion diagnostics have within drug development and therapeutic treatment. One aspect that is still to be examined is how personalized medicine and companion diagnostics will be integrated within comparative effectiveness research (CER). This is especially important as European regulatory bodies are embracing CER to help determine the best treatment for patients. Harry Glorikian, Scientia Advisors; Peter Homberg, Raupach & Wollert-Elmendorff; and Ruediger Weseloh, Merck Serono S.A. Geneva will investigate how biotech and diagnostics companies can successfully adapt to these new fast emerging regulatory demands.

The Soft Money Fountain: Creating an Overhang of Start-up Companies?
There is a growing trend in public and private funding towards seed and very early stage funding. The recent revival of corporate venture funds, tax incentive schemes supporting small start-ups, public grants and subsidies to get companies off the ground are in record numbers. Moderator Christian Schneider, Vesalius Biocapital will lead panelists Michael Brandkamp, High Tech Gruenderfonds; Klaus Stoeckemann, Peppermint Management GmbH; and Raphael Wisniewski, Edmond de Rothschild Investment Partners in a review of the implications of what may occur once companies outgrow these investment sources, from the perspective of the companies themselves and the biotech investment climate in general.

Another highlight of the day will be the presentations by pharma. Boehringer Ingelheim (CD Biopharmaceuticals), Boehringer Ingelheim (CD Licensing); Bayer Schering Pharma AG; Merck Serono; Novartis; Novo Nordisk; sanofi-aventis; AstraZeneca; Merck & Co., Inc.; Abbott; Baxter; Roche; and Pfizer will provide new and detailed information on their partnering areas of interest. These presentations will offers biotech firms a unique opportunity to gain new information that they can use to their advantage when approaching these pharma firms.

Lastly, the day 1 program features country seminars by Australia; Italy; Canada (Québec) and Israel (Jerusalem).

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe and BIO-Europe Spring®, the world's largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.



CONTACT:

EBD Group
Constantine Theodoropulos, +1 617-401-3116
[email protected]

KEYWORDS:   United States  Europe  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.